Results 21 to 30 of about 9,288,830 (350)

Endocrine Toxicities of Antineoplastic Therapy [PDF]

open access: yesCancers, 2021
In recent years, the prognosis of many solid tumors has improved markedly thanks to new treatment strategies, including tyrosine kinase inhibitors (TKIs) and immunotherapy [...]
Puliani G., Appetecchia M.
openaire   +3 more sources

Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

open access: yesJournal of Clinical Oncology, 2022
PURPOSE Patients with pretreated estrogen receptor (ER)–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer have poor prognosis.
F. Bidard   +28 more
semanticscholar   +1 more source

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

open access: yesThe Lancet Oncology, 2022
Summary Background Adjuvant abemaciclib plus endocrine therapy previously showed a significant improvement in invasive disease-free survival and distant relapse-free survival in hormone receptor-positive, human epidermal growth factor receptor 2 (HER2 ...
S. Johnston   +23 more
semanticscholar   +1 more source

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline

open access: yesJournal of Clinical Oncology, 2021
PURPOSE To develop guideline recommendations concerning optimal neoadjuvant therapy for breast cancer. METHODS ASCO convened an Expert Panel to conduct a systematic review of the literature on neoadjuvant therapy for breast cancer and provide recommended
L. Korde   +16 more
semanticscholar   +1 more source

Interrupting Endocrine Therapy to Attempt Pregnancy after Breast Cancer

open access: yesNew England Journal of Medicine, 2023
BACKGROUND Prospective data on the risk of recurrence among women with hormone receptor–positive early breast cancer who temporarily discontinue endocrine therapy to attempt pregnancy are lacking.
A. Partridge   +38 more
semanticscholar   +1 more source

Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients —A retrospective study

open access: yesFrontiers in Oncology, 2022
PurposeThe purpose of this study was to evaluate endocrine therapy and chemotherapy for first-line, maintenance, and second-line treatment of hormone receptor-positive HER-2-negative metastatic breast cancer (HR+HER-2-MBC) and the relationship between ...
Qiuyue Liu   +6 more
doaj   +1 more source

Factors influencing five-year adherence to adjuvant endocrine therapy in breast cancer patients: A systematic review

open access: yesBreast, 2022
Purpose This systematic review aimed to determine the rate and identify correlates of adherence and persistence over five years of treatment with adjuvant endocrine therapy in female breast cancer patients.
Izzati Yussof   +3 more
semanticscholar   +1 more source

Optimizing Adjuvant Treatment Recommendations for Older Women with Biologically Favorable Breast Cancer: Short-Course Radiation or Long-Course Endocrine Therapy?

open access: yesCurrent Oncology, 2022
Omission of radiotherapy among older women taking 5 years of adjuvant endocrine therapy following breast conserving surgery for early-stage, hormone sensitive breast cancers is well-studied. However, endocrine therapy toxicities are significant, and many
Susan G. R. McDuff, Rachel C. Blitzblau
doaj   +1 more source

Extended Adjuvant Endocrine Therapy in Early Breast Cancer Patients—Review and Perspectives

open access: yesCancers, 2023
Simple Summary Five years of therapy remains the standard for adjuvant endocrine therapy in early breast cancer. However, the recurrence risk remains elevated beyond this time period.
I. Bekes, J. Huober
semanticscholar   +1 more source

Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

open access: yesFrontiers in Oncology, 2021
PurposeTo evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective ...
Eunae Jeong   +4 more
doaj   +1 more source

Home - About - Disclaimer - Privacy